$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
恶液质如何治疗?日本推出首款恶液质治疗药Adlumiz
2025-10-19 11:44:20
Check Details
恶液质新药Adlumiz在国内能买到吗?
2025-10-19 11:44:20
Check Details
阿纳莫林是什么药?
2025-10-19 11:44:20
Check Details
阿纳莫林作用和功效
2025-10-19 11:44:20
Check Details
恶液质能治好吗?Adlumiz治疗恶液质效果怎么样?
2025-10-19 11:44:20
Check Details
日本首款恶液质新药Adlumiz上市,癌症恶病质的救星
2025-10-19 11:44:20
Check Details
2021抗癌新药阿那莫林上市,了解下这款抗癌新药背负的“使命”
2025-10-19 11:44:20
Check Details
首个治疗癌症恶病质的新药阿那莫林已上市,效果怎么样?
2025-10-19 11:44:20
Check Details
恶液质新药阿那莫林不出国怎么购买?阿那莫林治疗期间有什么禁忌?
2025-10-19 11:44:20
Check Details
日本首款癌症恶病质药物Adlumiz效果怎么样?恶病质有什么症状?
2025-10-19 11:44:20
Check Details
河北地区购买阿那莫林需要多少钱?疗效如何?
2025-10-19 11:44:20
Check Details
阿那莫林多少钱?杭州有吗?
2025-10-19 11:44:20
Check Details
1
2
...
17
18
19
20
21
22
23
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
2
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
3
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
4
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
5
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
6
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
7
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
8
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
9
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
10
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
11
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
12
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile